Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
2000 1
2001 3
2002 1
2003 3
2004 5
2005 2
2006 3
2007 3
2008 6
2009 10
2010 15
2011 23
2012 20
2013 71
2014 75
2015 88
2016 139
2017 183
2018 116
2019 51
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

712 results
Results by year
Filters applied: . Clear all
Page 1
Euglycemic Diabetic Ketoacidosis: A Review.
Modi A, Agrawal A, Morgan F. Modi A, et al. Curr Diabetes Rev. 2017;13(3):315-321. doi: 10.2174/1573399812666160421121307. Curr Diabetes Rev. 2017. PMID: 27097605 Review.
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Heerspink HJ, et al. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Circulation. 2016. PMID: 27470878 Review.
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. van Bommel EJ, et al. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):700-710. doi: 10.2215/CJN.06080616. Epub 2017 Mar 2. Clin J Am Soc Nephrol. 2017. PMID: 28254770 Free PMC article. Review.
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC, Yale JF. Goldenberg RM, et al. Clin Ther. 2016 Dec;38(12):2654-2664.e1. doi: 10.1016/j.clinthera.2016.11.002. Clin Ther. 2016. PMID: 28003053 Review.
SGLT2 Inhibitors May Predispose to Ketoacidosis.
Taylor SI, Blau JE, Rother KI. Taylor SI, et al. J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52. doi: 10.1210/jc.2015-1884. Epub 2015 Jun 18. J Clin Endocrinol Metab. 2015. PMID: 26086329 Free PMC article. Review.
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
DeFronzo RA, Norton L, Abdul-Ghani M. DeFronzo RA, et al. Nat Rev Nephrol. 2017 Jan;13(1):11-26. doi: 10.1038/nrneph.2016.170. Epub 2016 Dec 12. Nat Rev Nephrol. 2017. PMID: 27941935 Review.
EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV, Chilton RJ. Pham SV, et al. Am J Cardiol. 2017 Jul 1;120(1S):S53-S58. doi: 10.1016/j.amjcard.2017.05.011. Epub 2017 May 30. Am J Cardiol. 2017. PMID: 28606345 Free article. Review.
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
DeFronzo RA. DeFronzo RA. Diabetes Obes Metab. 2017 Oct;19(10):1353-1362. doi: 10.1111/dom.12982. Epub 2017 Jun 7. Diabetes Obes Metab. 2017. PMID: 28432726 Free PMC article. Review.
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial.
Development of SGLT1 and SGLT2 inhibitors.
Rieg T, Vallon V. Rieg T, et al. Diabetologia. 2018 Oct;61(10):2079-2086. doi: 10.1007/s00125-018-4654-7. Epub 2018 Aug 22. Diabetologia. 2018. PMID: 30132033 Free PMC article. Review.
712 results
Jump to page